Navigation Links
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

WAYNE, N.J. and SOUTH SAN FRANCISCO, May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that data evaluating the use of Nexavar® (sorafenib) tablets will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago.  

"Bayer and Onyx remain committed to researching the potential utility of sorafenib, and the number of abstracts being presented at this year's ASCO is a true testament to this commitment," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "The companies look forward to continuing to work together, and with various institutions and study groups, to further explore sorafenib.  Sorafenib has demonstrated efficacy in patients with unresectable liver cancer and advanced kidney cancer, and we remain committed to determine the potential of this therapy for patients."

Bayer and Onyx-sponsored, Phase 2 and 3 studies, and other research evaluating sorafenib, including investigational uses, being presented at ASCO include:

Efficacy and safety of intra-patient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC)

  • Professor Martin Gore, Medical Director, The Royal Marsden and Professor of Cancer Medicine at The Institute of Cancer Research, United Kingdom
  • Abstract number: 4609
  • June 5, 8:00 am – 12:00 pm, General Poster Session

Sorafenib plus chemotherapy for patients with advanced breast cancer previously treated with bevacizumab.

  • Clifford Hudis, M.D., Memorial Sloan-Kettering Cancer Center
  • Abstract number: 1009
  • June 6, 11:45 am, Oral Abstract Session<
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
2. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
3. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
4. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
5. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
8. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... DUBLIN , May 22, 2015 Research ... announced the addition of the "Latest Regulations ... report to their offering. This ... officially issued a guidance on international multi-center clinical ... , which has begun to be implemented on ...
(Date:5/22/2015)... -- Richmond Pharmacology is a university ... worldwide reputation for excellence in clinical trials. It ... reviewed medical journals. Its officers are engaged with ... about rules for transparency and publication of clinical ... Clinical research is conducted worldwide, therefore ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... Md. , May 26 The U.S. Food and Drug Administration ... liver injury in patients taking the weight-loss medication orlistat, marketed as Xenical and ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ... The FDA has approved a ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it will present at ... on June 9, 2010 , in New York, NY . ... provide an update on the Company,s marketed products and clinical programs. , ... The presentation will be webcast. To access ...
Cached Medicine Technology:FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 2FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 3ISTA Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:5/22/2015)... May 22, 2015 Memorial Day weekend is ... Insurance is offering some tips to help promote safe ... there will be 383 traffic fatalities this Memorial Day weekend. ... National Highway Traffic Safety Association: , , ... vehicle is wearing a seatbelt, whether they’re driving or riding ...
(Date:5/22/2015)... PA (PRWEB) May 22, 2015 According to ... a hub for drug related death, totaling almost 2,500 confirmed ... as reported by state officials, totals 2,489 deaths stemming from ... work out, Pennsylvania loses seven people every day to fatal ... has been singled out as one of the most rife ...
(Date:5/22/2015)... A Phase 3 French study, which ... Clinical Oncology (ASCO)’s annual meeting at the end ... patients who received bevacizumab in addition to the ... Genentech, Inc.) is an antibody that blocks angiogenesis ... used to treat many other cancers, including lung ...
(Date:5/22/2015)... Steven Winter Associates (SWA) Vice President ... selected by Consulting-Specifying Engineer (CSE) magazine as a young ... in the May/June issue of the publication. , This ... 40 and younger who have, and continue to make ... in other areas of their professional and personal endeavors. ...
(Date:5/22/2015)... 22, 2015 Puritan Medical Products, ... the medical, diagnostic, environmental, and forensics industries celebrates ... products in the US. At a time when ... the US, Puritan remains committed to designing and ... Guilford, Maine facility. , Since 1919, Puritan has ...
Breaking Medicine News(10 mins):Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2
... 14 (HealthDay News) -- In black Americans with type ... eye,s retina (retinal arteriolar narrowing) is associated with increased ... "Retinal arteriolar narrowing has long been described as one ... pressure] and cardiovascular disease," Dr. Monique Roy, of the ...
... A new study from the Regenstrief Institute and Indiana ... dementia are more likely to be living at home than ... that most individuals with dementia in the United States eventually ... Care for Older Adults With and Without Dementia" appears online ...
... , MONDAY, May 14 (HealthDay News) -- People ... significant improvement in the first six weeks, but may still ... a new study. Researchers analyzed data from 33 studies ... how treatment affects low-back pain. Their findings appear in the ...
... Using tiny solar-panel-like cells surgically placed underneath the retina, ... a system that may someday restore sight to people who ... diseases. This device a new type of retinal ... are equipped with a miniature camera and a pocket PC ...
... MI (May 9, 2012): Newly published results from a ... under development by Hygieia, Inc., demonstrate DIGS, potential to ... 2 or type 1 diabetes. DIGS automatically adjusted insulin ... Over the 12-week intervention period of the study, investigators ...
... May 11 (HealthDay News) -- A type of therapy that ... children but not severely obese teens, new research suggests. ... male) aged 6 to 16, who began "behavioral treatment" for ... method for assessing weight data that took into account the ...
Cached Medicine News:Health News:Individuals with dementia more likely to die at home than in nursing homes 2Health News:Back Pain Therapy Often Yields Early Benefits: Study 2Health News:New type of retinal prosthesis could better restore sight to blind, Stanford study says 2Health News:New type of retinal prosthesis could better restore sight to blind, Stanford study says 3Health News:New type of retinal prosthesis could better restore sight to blind, Stanford study says 4Health News:Automated insulin dosage titration system demonstrates positive clinical study results 2Health News:Sooner Is Better for Controlling Obese Kids' Weight: Study 2
... Post Operative Pin® Knee Brace (DxHDDLP) has a ... drop lock lever and laminate liner. The precision ... brace from migrating on the leg during ambulation. ... that controls flexion and extension in 5° increments ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
... The Drytex Adjustable Patella Donut ... a unique nylon core and polyester ... airflow. A trimable full-circumference donut provides ... who have neoprene based allergies or ...
... for total knees, meniscus repairs, regenerative chondroplasty, ... TROM gives easy-to-use range of motion control ... Rehab TROM can be used as a ... purchased separately be used with the TROM ...
Medicine Products: